West Palm Beach, FL, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has agreed to a multi-year partnership as the new title sponsor of The Palm Beaches Marathon. The U.S. Polo Assn. Palm Beaches Marathon, a race owned and managed by Ken Kennerly's K2 Sports Ventures, will be held in Downtown West Palm Beach, Florida, on December 13-14, 2025.USPA MarathonThis renowned marathon event is recognized for its beautiful views of the waterfront and palm-tree-lined streets and welcomes runners from across the country and around the world to the warmth of Florida during the cold winter months. It is also a qualifier for the legendary Boston Marathon."U.S. Polo Assn. is honored to be the Title Sponsor of The Palm Beaches Marathon, an iconic event that, like our brand, is deeply rooted in this vibrant community of Palm Beach County," said J. Michael Prince, President and CEO of USPA Global, the company that oversees the global, multi-billion-dollar U.S. Polo Assn. brand. "While our sport-inspired brand has a worldwide footprint in more than 190 countries, our heart and heritage are right here in The Palm Beaches, home to USPA Global, the United States Polo Association, and the USPA National Polo Center, the most prestigious polo destination in the world."The race weekend will include the 5K and 10K at 7:30 a.m. Saturday, December 13, followed by the featured Marathon, Half Marathon, and Marathon Relay on Sunday, December 14 at 6 a.m. Early registration is now open. Cost is $130 for the Marathon and $100 for the Half Marathon. The early registration fee for the 10K is $60, and $45 for the 5K. To register for The U.S. Polo Assn. Palm Beaches Marathon, visit palmbeachmarathon.com.A Health and Fitness Expo will coincide with race packet pickup on Friday, December 12, from 12 p.m. to 6 p.m. and Saturday, December 13, from 10 a.m. to 6 p.m. at the Meyer Amphitheatre, 104 Datura St., West Palm Beach. The Expo will feature the latest in health and fitness products and services, running apparel, and upcoming race information."We are excited to add a renowned global brand like U.S. Polo Assn. as the Title Sponsor of The Palm Beaches Marathon," Kennerly said. "This is a massive deal for the future of our race and its appeal to runners throughout the world. The Palm Beaches are a globally recognized blue-chip destination, and we are looking forward to continuing to grow the race not only in our community, but also on an international level."U.S. Polo Assn. brand products include apparel for men, women, and children, as well as accessories, luggage, watches, shoes, home furnishings, and more, with distribution across 190 countries through independent retail stores, department stores, U.S. Polo Assn. brand stores and e-commerce."Partnering with The Palm Beaches Marathon allows us to celebrate athletic excellence, community spirit, health and wellness, as well as the shared passion for sport that connects us locally and around the world. From the polo fields to the streets of Palm Beach, we are inspired by the athletes who give their all, and we look forward to sharing in the energy, camaraderie, and world-class competition that make The Palm Beaches Marathon truly special," Prince added.The race will support local charities, soon to be announced.WPBF 25, the Hearst-owned ABC Affiliate, will return as the Official Broadcast Station of the race and will provide extensive pre- and post-race coverage on all on-air and digital channels, as well as produce a live broadcast on Marathon race morning."WPBF 25 is thrilled to extend our partnership for a second year in a row as the Official Broadcast Station of the U.S. Polo Assn. Palm Beaches Marathon, reaffirming our commitment to help bring such a unique and exciting event like this to our community," said President and General Manager, Caroline Taplett. "Working together with our incredible partners, Ken Kennerly and the Marathon team, we are dedicated to promoting a more connected community, supporting local businesses, and inspiring participants, locally, nationally, and internationally to join us in beautiful South Florida for this one-of-a-kind experience."About U.S. Polo Assn.U.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center (NPC) in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.About The U.S. Polo Assn. Palm Beaches MarathonThe U.S. Polo Assn. Palm Beaches Marathon is a premier winter running event held annually in West Palm Beach, which features a range of race distances designed for runners of all abilities, including a full marathon, half marathon, 10K, 5K, and a 4-person marathon relay. Highlighted by a 100% flat, USATF-certified course, the Marathon serves as a Boston Marathon qualifier. The scenic route allows runners to experience West Palm Beach's vibrant downtown as it winds along palm-lined Flagler Drive, past historic neighborhoods, and features sparkling waterfront views. The event also supports community and charity efforts. Visit palmbeachmarathon.com.Contact InformationStacey KovalskyU.S. Polo Assn.skovalsky@uspagl.com(954) 673-1331Gary FermanSpecialty Sports(954) 558-5203SOURCE: U.S. Polo Assn. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - China Everbright Limited ("CEL" or "the Company", stock code: 165.HK) announced its Interim results for the six months ended 30 June 2025 ("the reporting period").Highlights of the 2025 Interim Results- Strong Growth: Total income reached HK$2,068 million, representing a significant increase compared with  the same period last year;- Turning Around from Loss to Profit: During the reporting period, the Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company was HK$399 million, successfully turning around from a net loss;- Fundraising Increase: The total assets under management (AUM) of CEL's funds amounted to approximately HK$119.4 billion, with new fundraising amounting to approximately HK$2,741 million;- Successful Exits: The total exits from funds and principal investments amounted to HK$2.018 billionï¼›with a MOIC (multiple on invested capital) of approximately 2.78 times;- Cost Control and Efficiency Enhancement: Enhanced lean management led to a 10% year-on-year decrease in operating costs and a 38% year-on-year reduction in finance costs;- Adequate Liquidity:  The Company had cash and cash equivalents of approximately HK$8.1 billion;- Steady Dividend:  An interim dividend of HK$0.05 per share for 2025.In the first half of 2025, China's private equity industry entered a more stable stage of development. Leveraging its strengths as patient capital, CEL maintained strategic focus, seized market opportunities with precision, and promptly adjusted its fundraising, investment, management, and exit strategies. By consolidating its core businesses, gradually unlocking value potential, and significantly improving overall operational efficiency, the Company achieved a strong rebound in performance.During the reporting period, CEL realised total income of HK$2,068 million, representing a significant increase of HK$2,182 million from the same period last year. This was mainly due to a significant increase in investment income, which fully demonstrated the Company's sound investment vision and solid foundation in long-term investing. The Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company amounted to HK$399 million, successfully turning around from a net loss attributable to shareholders of HK$1,282 million in the same period last year, representing a significant improvement in performance.Meanwhile, the Company continued to strengthen its refined management, sustaining healthy and steady business development. During the reporting period, operating costs represented a year-on-year decrease of 10%, with proactive leverage reduction measures implemented. The gearing ratio decreased by 2% compared with the end of 2024, while finance costs fell 38% year-on-year, demonstrating significant results in cost control and efficiency improvement. As at the end of June 2025, the Company had cash and cash equivalents of approximately HK$8.1 billion, representing sufficient liquidity.By concentrating its resources and business focus on high-potential products, the Company further reinforced its core business. During the reporting period, with new fundraising amounting to approximately HK$2,741 million, the total AUM of CEL’s funds amounted to approximately HK$119.4 billion, managing 72 fund products and covering primary market funds, secondary market funds, and fund of funds. During the reporting period, the Company invested in a total of 9 projects and exited, fully or partially, from 46 project.Following the practice of sharing the Company's operating results with shareholders, the Board declared interim dividend of HK$0.05 per share for 2025 (2024 interim dividend: HK$0.05 per share).Business Highlights in the First Half of 2025Firstly, CEL Harnessed the Strengths of Group-Based Operations to Enhance Fundraising SynergyIn the first half of 2025, the Company successfully launched the Huaian Hongze Guangqi Fund and the Xiamen Marine High-Tech Industrial Development Fund, with a total scale of RMB2.5 billion. The Huaian Fund targets growth-stage projects in the areas of new energy, new materials, and intelligent manufacturing, with its first round of capital contribution completed in the first half of the year. The Xiamen Marine Fund is dedicated to incubating and transforming scientific and technological innovations in the marine sector, driving the high-quality development of the marine economy. At the same time, several other funds have been approved and are progressing smoothly, following the established plan.Secondly, CEL Strengthened Core Businesses to Drive Robust Recovery in PerformanceDuring the reporting period, the Company total exits from funds and principal investments amounted to HK$2.018 billion. This include the full exit from Xpeng Motors, DAPU Telecom, and Taboola, alongside partial exit from iSoftStone, Dekon Food and Agriculture, 4Paradigm, and other projects. With a MOIC (multiple on invested capital) of approximately 2.78 times, these exits significantly boosted the DPI of multiple funds, generating substantial returns for LPs. Several listed projects, including Circle, Dekon Food and Agriculture, and NetEase Cloud Music, delivered strong market performance in the first half of the year, making notable contribution to the Company's investment returns. In the first half of the year, secondary market funds expertly capitalised on structural opportunities, achieving impressive investment performance. Notably, the Everbright Convertible Bond Opportunity Fund ranked second among similar funds in Barclays' performance rankings.Thirdly, CEL Anchored Strategy Around Scientific and Technological Innovation, With a Particular Focus on Key Industry SectorsGuided by deep industrial insight and a forward-looking strategic vision, the Company accelerated its investment activity in the first half of the year. It targeted emerging strategic industries such as artificial intelligence, chips and semiconductors, and biomedicine, with a total investment of approximately HK$264 million by funds. We have nurtured and supported a number of technology leaders, including Yangtze Memory and Wuhan Xinxin (both prominent domestic memory chip producers), HengYi Biotech (a company engaged in the research and development of innovative drug for tumors and autoimmune diseases), J-Sensor (astrategic supplier of domestic industrial automation modules and core sensors for new energy vehicles), and Tec-Do (a service provider in the field of big data and BI), among others. These investments reflect our commitment to strengthening China’s science and technology enterprises. Meanwhile, CEL supported excellent sub-funds such as Jinyi Capital and Eastern Bell Capital through its FoF platforms. These FoF investments allow us to fully leverage the advantages of resource amplification, risk diversification, and diversified returns.Fourthly, CEL Optimise Business Management to Unlock Growth MomentumIn the first half of the year, the Company continued to optimise its financing structure and took full advantage of the domestic interest rate cut cycle, issuing RMB3 billion in the first tranche of its 2025 medium-term notes at a coupon rate of 2.09% per annum — the lowest coupon rate in the Company's bond issuance history. During the reporting period, the Company's overall financing cost declined by 133 basis points year-on-year to 3.14%, while its finance costs reduced by 38% year-on-year. Operating costs also recorded year-on-year decrease of 10%, underscoring the solid progress made in reducing costs and increasing efficiency. The Company continued to optimise its risk management framework. CEL advanced the classification of risk assets, reinforced dynamic valuation management, and established a risk monitoring and early warning system, thereby improving the effectiveness of risk prevention and control across the full business cycle.Fifthly, CLE Enhanced Public Services and Upgraded Commercial Consumption.CEL leveraged its industrial strengths to enhance the quality of its products and services, catering to the growing demand for consumer services among citizens. In the commercial consumption arena, EBA successfully launched 18 "IMIX Park" shopping centres across nine cities nationwide,managing approximately 2.6 million square metres in total. These centres created approximately 37,700 jobs, attracted approximately 121 million customer visits, and hosted more than 4,500 tenant merchants in the first half of 2025. During the reporting period, Phase I of the "Zhongguancun ART PARK IMIX Parks", a flagship consumption infrastructure and urban renewal project in Beijing, opened smoothly, significantly upgrading the consumer experience and giving a strong boost to domestic demand.Sixthly, Key Portfolio Companies Maintain Stable Growth with Strong ResilienceThe core business of China Aircraft Leasing Group Holdings Limited (CALC) progressed steadily with remarkable improvements in operating quality and efficiency. The net profit attributable to shareholders recorded a year-on-year increase. As of June 30, 2025, CALC’s fleet reached 181 aircraft, leased to 41 airlines across 22 countries and regions. Everbright Senior Healthcare has been seizing the development opportunities in China's healthcare industry. As of 30 June 2025, Everbright Senior Healthcare has 237 institutions of various types in 49 cities across the country, it managed more than 30,000 beds, with occupancy rates increasing by 1.77%. Meanwhile, Terminus continued to deepen the integration of AI technology across multiple industries, driving intelligent transformation and implementing localised AI applications and digital-intelligent solutions, while receiving multiple authoritative certifications.Seventhly, CEL Strengthened ESG Framework to Promote Sustainable DevelopmentDuring the reporting period, CEL continued to promote the construction of its ESG system. the Company maintained an "A" rating in the MSCI ESG Rating and received the "BEST ESG (S)" award from the Hong Kong Investor Relations Association (HKIRA). The Company earnestly fulfilled its role as a corporate citizen by leveraging its own capabilities, organizing and participating in 46 cultural and social welfare activities in the first half of the year, serving over ten thousand people, and upholding high standards in discharging its social responsibilities.In the first half of 2025, under the strong leadership of the Everbright Group, the guidance of the Board of Directors, and the collective efforts of all employees, the Company achieved significant improvements in operational efficiency and quality, with new drivers of growth continuing to strengthen, resulting in hard-won achievements. As China's economy continues to improve and policy support intensifies, the Chinese private equity industry will embark on a new journey of high-quality development. CEL will seize market opportunities, capitalise on the momentum, and lay a solid foundation for a strong start to the 15th Five-Year Plan. In the second half of the year, CEL will continue to adhere to the overall principle of seeking progress while maintaining stability, continue to focus on revenue growth and cost control, optimise operational management, seize opportunities in key business areas such as fundraising, investment, management, and exit, leverage the cross-border platform and the synergistic advantages of the group, cultivate long-term patient capital, and advance the "five major financial initiatives", through scientific strategic planning, professional investment teams, and rigorous risk management,  and continuously create value for shareholders.China Everbright Limited, https://www.everbright.com/en [SHSE:601818][HKEX:00165][OTCPK:CEVIF][OTCPK:CEVIY] Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights (Unaudited)(HKD Thousand)Six months ended 30 June20252024Revenue122,775135,347Gross Profit47,27748,767Profit Attributable to Owners of the Company8,17218,510Gross Profit Margin39%36%Basic Earnings per Share (HK cents)0.581.31HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com)  Dynasty Fine Wines Group Limited (“Dynasty” or the “Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its unaudited interim results for the six months ended 30 June 2025.In the first half of 2025, as the Group strengthened the effort for dry white market in coastal region and the new launch of white wine and sparkling wine products, the Group’s sales revenue of white wine products maintained a good momentum. But due to the impact of macroeconomy, fluctuations in consumer market in the PRC, as well as increase in marketing and promotion expenses, the Group's revenue for the first half of 2025 decreased by 9% to approximately HKD 123 million compared to the same period in 2024. Profit attributable to owners of the Company declined by 56% to approximately HKD 8.2 million year-on-year. Basic earnings per share were approximately HK0.58 cents per share. The overall gross profit margin increased to 39% from 36% for the corresponding period in 2024, mainly due to optimisation of product mix during the period.Sales of white wines products of the Group served as the Group’s primary revenue contributor during the period. Sales revenue of red and white wines products accounted for approximately 41% and 54% of the Group’s overall revenue respectively for the period. During the period, the gross profit margin of red wine products and white wine products were 38% and 39% respectively.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the period under review, the Group continued launching new products and carrying out product upgrade, that can better suit different palates, and cater for consumers with different spending power. That was done with an aim to invigorate the brand, as well as consolidating the image of Dynasty representative of domestic grape wine brand. The Group produced a wide range of more than 100 wine products under the “Dynasty” brand to meet the demands and preferences of different consumer groups mainly in the mass-market segments in the PRC wine market. During the period under review, the Group launched a new high-end product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. During this period, the Group continued strengthening cooperation with the Wine Association and carried out activities such as "Dragon University Tours" to further expand the brand's awareness and reputation among young people. Based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of "tea and wine fusion", has captured market attention with its unique craftsmanship. Based on white wine, this Tea-flavoured wine infuses the aromas of jasmine and Pu'er tea, creating a new oriental flavour within the traditional sparkling wine landscape. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Tianxia Winery won industry praise for their unique flavor and exquisite craftsmanship.Further to our commitment to core wine business in the PRC, the Group will develop new alcoholic beverages segments such as sauce-flavour baijiu, yellow wine and special yellow wine – Chenpi wine, through the newly set up joint venture companies, so as to diversify the sources of revenue. Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in Tianjin core-market with enthusiastic responses and will be further strategically promoted to other regions in the second half of the year. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness. For the yellow wine project, after planning, a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu will be under construction in the second half of 2025. Upon completion of the construction works, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry, and achieve a major strategic move towards high-quality development of the wine industry.Regarding E-commerce sales, the e-commerce team of the Group comprehensively operated online stores on traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based ecommerce platforms, including RED, Kuai and TikTok during the period under review. The Group’s autonomous brand communications could continue to gain the attention of mainstream consumer groups and demographic segments, and enhance effective market penetration of the Group’s products targeted at young consumers. The e-commerce team also actively cultivate e-commerce live broadcasting talents to further expand its sales channels so as to build up a new customer base.In addition, during the period under review, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea-flavoured Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series -Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to the second half of 2025, the Group will continue to focus on market and consumer demand and promote product quality through technological innovation. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to proactively develop new marketing prospects through innovation in product categories and consumption scenarios, and cross-industry co-operations in order to boost sales volume, which is in line with the country’s effort to promote domestic consumption and release the consumption growth potential.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

Healthy pipeline, diversification and cost discipline position the Company for long-term growthKey Financial Performance Highlights for the Financial Year (FY2025):- Group’s total revenue for the financial year is RM222.7 million, mainly driven by the e-mobility and energy storage segment, supplemented by the electronics segment.- Recorded LAT of RM40.9 million for Q4FY2025 and LAT of RM27.2 million for the financial year.BANGI, Malaysia, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, Genetec Technology Berhad (“Genetec” or the “Company”), today announced its financial results for the year ended 30 June 2025 (“FY2025”). The Company reported a gross profit of RM12.7 million for FY2025, supported by continued deliveries in the e-mobility and energy storage segments. The Company recorded a loss after tax (LAT), mainly reflecting higher logistics costs and non-operational, one-off expenses, while underlying fundamentals remain intact.Performance was affected by logistics constrains and one-off costs. Despite this, the Company continued to invest in strengthening its capabilities and supporting future project scopes. Profitability is expected to normalise in FY2026 as markets stabilise and as projects are executed effectively. Genetec is also reinforcing its organisation by bringing in experienced professionals into strategic roles, aimed at broadening capabilities and supporting its long-term diversification strategy.Healthy Orderbook through Diversified MarketsThe Company’s order and tender books remain intact and healthy, underpinned by recurring orders from existing clients as well as new opportunities from a more diversified client base across multiple industries and regions.Deepening Engagement with Existing ClientsAlongside diversification, Genetec continues to strengthen partnerships with its existing clients. Recurring orders and new programme awards reflect the trust and confidence these clients place in Genetec’s execution capabilities and proven track record.Global Manufacturing Trends Creating TailwindsGlobal geopolitical shifts are leading manufacturers across industries to re-evaluate their production footprints and enhance operational resilience. This trend is fuelling greater demand for automation solutions that are flexible, cost-competitive, and consistently high in quality. With its Malaysia-based production model, strong international track record, deep technical know-how, and agile manufacturing capabilities, Genetec is well-positioned to support clients as they navigate and adapt to these evolving requirements.Positive Outlook for BESS PipelinesThe Battery Energy Storage System (BESS) segment continues to gain momentum, with Genetec executing projects across domestic and international markets, and seeing growing local interest in BESS solutions for peak shaving following the recent tariff revision.Chief Executive Officer and Co-founder of Genetec, Chin Kem Weng commented, “FY2025 was a year of investment and transition. We made deliberate strategic choices to strengthen our foundation, safeguard delivery timelines, and support new project scopes. While these factors impacted margins in the short term, they reinforce our capabilities and credibility as a trusted partner. We expect profitability to normalise as market stabilise and as we build on execution experience.”“At the same time, our pipelines remain healthy, supported by recurring orders from existing clients and new opportunities across diversified industries and regions. Our inclusion in both the conventional and Shariah FTSE4Good Bursa Malaysia indices reflects the strength of our governance and sustainability practices. As Genetec approaches our 30th year in business, we remain committed to creating long-term value for clients, shareholders, and stakeholders.”About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/.Issued on behalf of Genetec Technology Berhad by Narro CommunicationsFor media enquiries on Genetec Technology Berhad, please contact:Farah Shahrul                                               Narro Communications                               E: farah@narrocomms.com                           Joyce ShaminiNarro CommunicationsE: joyce@narrocomms.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company's core product, HuaTangNing (dorzagliatin tablets), accelerated. The Company’s independent operational capabilities improved significantly. R&D progress advanced smoothly and the Company’s financial performance achieved breakthrough growth, laying a solid foundation for long-term sustainable development.Sales of HuaTangNing increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achieved significant results.Following the termination of the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB 1,243.5 million, achieving a profit of RMB 1,183.9 million for the first half of the year. This is the Company's first profit during the performance period.A real-world study (BLOOM) involving 80 centers and 2,000 patients with Type 2 diabetes conducted in China further demonstrated the broad applicability and safety of dorzagliatin.A registration application has been submitted in Hong Kong for Dorzagliatin 75mg (brand name: MYHOMSIS®), aiming to extend its presence across Greater China and Southeast Asia.Gross profit margin improved significantly, as production scale and operational efficiency continued to be optimized.“The first half of 2025 was a critical stage in Hua Medicine’s transformation and development. Following the full takeover of the commercialization of HuaTangNing, the Company achieved double-digit growth in sales and revenue through its independently established sales team, thereby validating the effectiveness of the new business model. We have also submitted a new drug application in Hong Kong, China, laying the foundation for dorzagliatin to expand from China to Southeast Asia and the global market,” said Dr. Li Chen, founder and CEO of Hua Medicin “Dorzagliatin has continued to demonstrate broad therapeutic potential in real-world studies, and new evidence has been found in basic research regarding diabetes remission, cognitive improvement, lipid improvement, and muscle gain, further consolidating Hua Medicine’s global leadership in GKA research and development and treatment. In the future, Hua Medicine will continue to focus on diabetes and the entire field of metabolic diseases, driving innovation through research and development and market expansion to bring the benefits of China's original innovative drugs to more patients worldwide.”   Business Highlights and Operational ProgressCommercialization transformation achieved remarkable results, with doubling of sales and profits.Effective from January 1, 2025, the Company terminated its exclusive promotion service agreement with Bayer and fully took over the commercialization of HuaTangNing (å''å ‚å®'®) in China. During the Reporting Period, with unit prices remaining consistent with the same period in 2024, sales of HuaTangNing reached 1,764,000 packs, a year-on-year increase of 108%. Net sales reached RMB217.4 million, a year-on-year increase of 112%. Leveraging strong commercial execution and continuously improving operational efficiency, the Company is moving toward profitability. Hua Medicine has successfully transitioned to a fully independent commercialization phase, confirming growing market demand and the efficient execution capabilities of its independent sales team.Sales of HuaTangNing continued to benefit from its inclusion in China’s National Reimbursement Drug List (NRDL), which took effect in January 2024. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption.Due to expanded production scale and improved cost efficiency, the Company's gross profit margin increased to 54.2%, higher than 46.5% in the same period last year.With sales revenue growing 112% year-on-year, the Company's sales expenses during the Reporting Period were RMB64.2 million for the six months ended June 30, 2025, growing only 5% compared to the same period last year. The composition of our selling expenses for the six months ended June 30, 2025 changed significantly from the same period in 2024 due to the Company incurring selling expenses directly as a result of assuming sole commercialization responsibilities for HuaTangNing in China, while no longer owing promotion expenses to the former commercialization partner. These figures also reflect a significant positive trend towards profitability and demonstrate our business strategy of optimizing profitability by controlling commercialization sales expenses of HuaTangNing and maximizing production efficiency, where our selling expenses in the first half of 2025 represent approximately 29.5% of total revenue whereas in the first half of 2024, our selling expenses represented approximately 59.5% of total revenue. After terminating the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB1,243.5 million and transitioned to self-driven growth. Hua Medicine achieved a pre-tax profit of RMB 1,183.9 million for the first half of the year, marking a key milestone of Hua Medicine towards sustainable profitability.As of June 30, 2025, the cash balance was RMB1,022.8 million, laying a solid foundation for the Company's future R&D and commercialization initiatives.Clinical research continues to deepen, with new evidence supporting treatment potentialHua Medicine is conducting multiple post-marketing studies to evaluate the long-term safety and effectiveness of dorzagliatin across diverse patient populations, both in monotherapy as well as in combination with other popular approved anti-diabetic drugs, such as GLP-1 receptor agonists, insulin, DPP-IV inhibitors and SGLT-2 inhibitors. These studies are generating new clinical insights into glucose control, cognitive outcomes, and potential for diabetes remission.A real-world study (BLOOM) is being conducted in 2,000 patients with Type 2 diabetes across 80 centers in China. BLOOM has already completed one-year follow-up in over 1,000 participants. In the real-world setting, BLOOM further demonstrates the broad applicability and safety of dorzagliatin. Patients receiving dorzagliatin in routine clinical practice present with a heterogeneous mix of comorbidities, including various cardiovascular and renal disorders and are managed with multiple concomitant medications. In addition to metformin, more than 60% of patients concurrently used SGLT-2 inhibitors, insulin, GLP-1 receptor agonists, or DPP-IV inhibitors and other anti-diabetic drugs with dorzagliatin. In monotherapy or in combination with the popular above-mentioned anti-diabetic drugs, dorzagliatin was generally well tolerated, and its safety profile remained consistent with previously established data.Hua Medicine presented new data at the 2025 American Diabetes Association (ADA) conference, reinforcing dorzagliatin’s potential as a disease-modifying therapy. Insights into the novel mechanism of action (MOA) of dorzagliatin as a therapeutic GKA were published in Diabetes.Research and Development Pipeline and Future OutlookThe company filed its application for registration of dorzagliatin 75mg in Hong Kong as MYHOMSIS®, aiming to extend its presence across Greater China and southeast Asia.We are continuing expansion on our product pipeline through development of fixed dose combination of metformin and dorzagliatin for patients who have failed to control blood glucose levels while using high dose metformin (daily dose>1500 mg). In the loose dose combination study-DAWN Trial, dorzagliatin add-on to metformin provided HbA1c reduction of greater than 1% and post meal glucose reduction of greater than 5 mmol/L. These desirable glycemic control levels coupled with a very safe 0.8% hypoglycemic rate would suggest strong potential demand for a branded oral anti-diabetic medication using a convenient fixed dose combination of dorzagliatin and metformin. The Pre-IND submission has been achieved in August 2025, and we are expected to initiate the bioequivalence study in early 2026.We are also advancing the combination of dorzagliatin with GLP-1RA, SGLT-2 inhibitors, insulin and DPP-IV inhibitors through combined effects in collecting real world evidence and proof of concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indications into other diseases in metabolic disorders, such as obesity and MASH.We continue to enhance our collaborations with leading international research institutions. A Phase I investigator-initiated trial supported by the Group and conducted at the University of Pennsylvania – designed to evaluate the efficacy and safety of dorzagliatin in patients with cystic fibrosis-related diabetes (CFRD) – has received clearance from the U.S. FDA.We will continue our engagement in diabetes prevention, opportunities in metabolic disorder related neurodegeneration disease and eventually find a new way to increase healthy life span and longevity in humans.We continue to invest in digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.As illustrated in our product pipeline chart, we will continue to advance our R&D efforts for both dorzagliatin and our 2nd generation GKA on our own as well as in collaboration with academic and strategic partners. We are working on the registration of dorzagliatin in Hong Kong and continue to seek partnerships in Southeast Asia and Belt and Road nations. In addition, we will continue our business development efforts on our 2nd generation GKA for the global markets based on the initial success of the Phase 1 single-ascending dose study in the United States and the initiation of our Phase 1 multiple ascending dose study planned for late 2025 or early 2026.Financial SummaryAs of June 30, 2025- Bank balances and cash amounted to approximately RMB 1,022.8 million.- Total revenue was approximately RMB217.4 million, representing a year-on-year increase of 112%. Sales of HuaTangNing (å''å ‚å®'®) reached 1,764,000 packs, representing a year-on-year increase of 108%.- Total gross profit was approximately RMB117.8 million, representing a year-on-year increase of 147%. Gross margin was approximately 54.2%, increased by approximately 7.7 percentage points, as compared with the six months ended June 30, 2024.- Total other income amounted to approximately RMB1,254.6 million , of which Bayer's one-time release of previously deferred income was RMB1,243,5 million.- Total expenditures were approximately RMB187.1 million, of which research and development expenditure was approximately RMB65.8 million.- Profit before tax was approximately RMB1,183.9 million, representing  approximately 932% for the six months ended June 30, 2025Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestors E-mail: ir@huamedicine.comMedia E-mail: pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings Limited (0697.HK, hereinafter referred to as “Shoucheng Holdings”), Beijing Shoucheng Robotics Technology Industry Co., Ltd. (hereinafter referred to as “Shoucheng Robotics”), IAT Automobile Technology Co., Ltd. (300825.SZ, hereinafter referred to as “IAT”), and Beijing IATROBOT Technology Co., Ltd. (hereinafter referred to as “IATROBOT”) officially signed a strategic cooperation framework agreement.The four parties will leverage their respective strengths to carry out comprehensive cooperation in technological innovation, application deployment, industry chain collaboration, and talent cultivation within the robotics sector, jointly accelerating the development of new business models in the “Robotics + Automobiles” field.I. Industry Background: Robotics Entering the Acceleration Phase of Application DeploymentAt present, the global robotics industry is in a stage of rapid development, with national strategies and policies being introduced intensively. On August 26, the State Council officially released the Opinions of the State Council on Deeply Implementing the “AI+” Initiative (Guo Fa [2025] No. 11), which explicitly calls for promoting the extensive and in-depth integration of artificial intelligence with various industries and fields across the economy and society, and accelerating the formation of new models of intelligent economy and intelligent society characterized by human-machine collaboration, cross-industry integration, and co-creation.Under this national strategy, the robotics industry is shifting from “technological breakthroughs” to “application deployment.” Automobiles and robotics, as two highly complementary industries, are increasingly showing a trend of cross-sector integration. The cooperation between Shoucheng Holdings and IAT Group, under the dual drivers of favorable policy and strong market demand, will inject new momentum into robotics applications across key segments such as R&D, manufacturing, transportation, and mobility services.IAT is a leading enterprise in China’s automotive design field and the only independent automotive design company listed on the A-share market. The company provides full-process services ranging from complete vehicle R&D and design to core component manufacturing, while pursuing a globalization strategy of “technology + supply chain.” According to public information, IAT has served more than 80 clients and participated in the development of nearly 500 vehicle models. Its clients include major OEMs such as FAW, Dongfeng, BAIC, Geely, emerging EV brands, as well as joint-venture automakers. This highlights IAT’s strong OEM resources and delivery capabilities across the automotive value chain.At the same time, through its subsidiary — Beijing IATROBOT Technology Co., Ltd. — IAT has officially entered the robotics sector. IATROBOT is dedicated to building an integrated R&D, design, and simulation training platform, capable of supporting multi-scenario robotics development from simulation and testing to optimization. The company has already launched multiple R&D projects, including wheeled robots, underwater robots, drilling robots, and pet-care robots, demonstrating its potential in cross-scenario development and industry collaboration. The involvement of IATROBOT expands the scope of this cooperation beyond traditional automotive design, providing important support for the integration of robotics R&D, simulation, and automotive industrialization.By partnering with IAT and IATROBOT, Shoucheng will be able to embed robotics technologies deeply into the core stages of the automotive value chain, such as vehicle manufacturing, intelligent assembly, and production line testing. This will enable robots to truly enter the production line and accelerate industrial adoption. This strategic cooperation is not merely a technological connection — it leverages IAT’s extensive OEM client network to move robotics scenarios from “next-door demonstrations” directly into the “factory workshop,” bridging the crucial pathway between R&D validation and scaled industrial delivery.II. Key Areas of Cooperation: Balancing R&D Breakthroughs and Application DeploymentGuided by the State Council’s “AI+” Initiative, the four parties will anchor their collaboration on the full chain of “technology R&D — industrial application — ecosystem co-construction,” working together to drive industrial innovation. The cooperation will focus on the following areas to promote the deep integration of robotics and automobiles:(1) Technological Innovation and Joint R&DThe four parties will jointly build an integrated robotics R&D and simulation platform, drawing on the comprehensive R&D system of the automotive industry. The focus will be on achieving breakthroughs in key areas such as motion control, structural optimization, automotive-grade components, and large-scale manufacturing. Leveraging NVIDIA Isaac/Omniverse technology, the parties will co-develop an integrated simulation training platform that not only supports simulation of robotics applications in automotive R&D, manufacturing, and testing, but also enables cross-scenario simulations such as collaborative operations between autonomous driving vehicles and logistics robots.In addition, a mechanism for data and outcome sharing will be established: Shoucheng Holdings will provide operational data resources from transportation and mobility scenarios, while IAT will contribute expertise in automotive engineering and robotics R&D, together forming a complete closed loop spanning simulation — R&D — validation — production line application.(2) Priority Procurement and Synergy MechanismAcross R&D design, simulation training, complete machine and component supply, the four parties will adopt a priority procurement mechanism, under which signatories will be given preference as partners under equivalent conditions. Shoucheng Holdings and Shoucheng Robotics will focus on product promotion, distribution, and supporting services, while IAT and IATROBOT will concentrate on technology R&D, engineering validation, and customized whole-machine development.The parties will also work together to advance secondary development of robotic systems, ensuring optimal adaptation of robotics products to scenarios such as automotive production lines, intelligent assembly, and line testing. Through division of labor and collaborative mechanisms, a complementary cycle of product supply — technological innovation — application feedback will be established, accelerating the conversion of results and enhancing commercialization efficiency.(3) Talent DevelopmentLeveraging the research and industrial platforms of Shoucheng, IAT, and their partners, the four parties will jointly carry out technological problem-solving, simulation training, and application pilots, providing researchers and engineers with cross-industry, cross-scenario practical environments. Regular technical seminars and industry forums will be held, inviting experts and upstream and downstream enterprises to participate, thereby establishing a joint talent development mechanism. This initiative aims to cultivate a new generation of young researchers with both automotive engineering backgrounds and practical experience in robotics industrialization, laying a solid talent foundation for long-term growth.(4) Expanding Development HorizonsThe four parties will closely align with national strategies for “AI+” and robotics industry development, with a focus on scaling up “Robotics + Automobiles” applications in R&D, manufacturing, testing, and mobility services. Building on this foundation, the cooperation will gradually extend into broader fields such as smart transportation, intelligent manufacturing, healthcare, education, and public services, covering the design, R&D, production, testing, and commercialization of robots and core components. At the same time, by integrating capital and industry, the parties will drive coordinated upgrades across the value chain, ultimately forming a full-cycle closed loop from R&D validation to large-scale application. This will create a demonstrative “Robotics + Automobiles” application matrix, achieving mutual benefits and long-term value creation.III. Strategic Significance: Establishing a New Benchmark for Robotics ApplicationsThe greatest value of the robotics industry lies in real-world applications, and “Robotics + Automobiles” stands out as one of the most promising and high-potential application directions. From complete vehicle R&D to intelligent manufacturing, from traffic scheduling to smart mobility, robots will create tremendous value across the entire automotive value chain.Shoucheng Holdings, leveraging its capital platform, ecosystem resources, and industrial fund advantages, has invested in leading domestic enterprises such as Unitree Robotics, Galbot, Noetix Robotics, Galaxea-AI, and Booster Robotics, equipping it with the capability to integrate frontier technologies. Shoucheng Robotics has established collaborations with hundreds of high-quality upstream and downstream enterprises, making it one of the most comprehensive resource-linking platforms in China. IAT and IATROBOT, in turn, bring mature automotive engineering systems into robotics R&D and industrialization. Together, the combined strengths of both sides will form a complete pathway of “R&D — iteration — application — scale-up.”By joining forces with IAT, Shoucheng will further integrate its scenario resources and industrial ecosystem with IAT’s expertise in vehicle R&D, engineering capabilities, and industrialization experience. Over the next one to two years, the cooperation will focus on the deep integration of “Robotics + Automobiles,” taking the lead in demonstrating large-scale applications across vehicle R&D, production and manufacturing, smart transportation, and mobility services. This will accelerate the transition of robotics from laboratories to industrialization and large-scale deployment, creating a demonstrative “Robotics + Automobiles” application matrix. At the same time, the cooperation will also look to the international market, bringing Chinese solutions to the global stage, fostering new quality productivity, and generating long-term value for shareholders.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Tianneng Power International Limited (the “Company”, together with its subsidiaries, collectively referred to as the “Group” or “Tianneng”), (Stock Code: 00819.HK) releases its interim report for the six-month period ended 30 June 2025.In the first half of 2025, adhering to the Group’s vision of Strategic Guidance and Reformation Breakthrough, Tianneng coordinated the three-wheeled strategy of Industry, Technology, and Capital. While solidifying the core competency of the lead-acid battery business, the Group also accelerated the expansion of overseas markets, released the Group’s built-up potential in new-energy battery, deepened the vertical construction of the battery recycle system, and drove the diversification of products and sustainability.Within the reporting period, the Group made a strategic pivot to reduce the trade business, achieved RMB 21.168 billion in revenue for the manufacturing business, which was stable compared to the same period in 2024, accounting for approximately 87.5% of the total revenue within the sector. In terms of the trade business, the Group realized an overall revenue of RMB 30.24 billion, which represented an 89.47% decrease from the same period of 2024. Within The manufacturing sector, the high-end eco-friendly battery business remained stable, providing a resilient financial support for the Group. The emerging businesses experienced significant growth, among which the Li-ion battery business achieved a revenue of RMB 0.501 billion, representing a 174.58% growth from the same period of 2024. Within the reporting period, the Group achieved a gross profit of RMB 2.537 billion, which is stable compared to the same period of 2024. In terms of operating cash flow, the Group achieved RMB 0.891 billion of net inflow, compared to a net outflow of RMB 0.162 billion in the same period of last year. Overall, in the first half of 2025, Tianneng demonstrated strong resilience, developmental momentum, and strategic commitment in a complex external environment.Internationalisation Accelerated, Overseas Expansion Bore FruitsInternational expansion is a vital fulcrum of the Group in strengthening global competitiveness and achieving incremental leaps. In the first half of 2025, the overseas business experienced remarkable growth with continuous positive feedback, achieving a revenue of RMB 0.226 billion, representing a 75.39% growth from the same period of 2024.Within the reporting period, guided by local demands, the Group accelerated its overseas expansion with global industrial resources, and set up operational teams in countries such as Thailand, Vietnam, and Turkey while developing a sales network in major areas including the Asia-Pacific, Europe, North America, the Middle-East and Africa. In addition, the Group’s production base in Vietnam is being constructed in an orderly manner while the capacity of the assembly base is robustly released, laying the groundwork for future developments in the region. The Group has developed customised products based on specific local demands and emphasised building localised operational teams, while advancing its “Overseas Service” strategy, and systematically constructed localised standards. With these developments, the Group was able to optimise its global supply chain and release future growth potentials.Core Business Stable and Resilient, with Promising Growth MomentumWithin the reporting period, the Group pursued a path of “Stability and Growth Duality” under a complex external environment and industrial structure re-balancing. The high-end eco-friendly battery business demonstrated resilience, achieving a revenue of RMB 18.292 billion, providing the vital financial stability for the Group. The high-end eco-friendly batteries are sealed, maintenance-less lead-acid batteries built with the Group’s innovation in design and manufacturing, highly adapting to the demands of the light electric vehicle market, with their cost and performance superiority, are also widely utilised in various fields, including backup power supplies, automobile batteries, and special-purpose industrial power batteries.The Group solidified its competencies in the core business, upgraded its intelligent manufacturing capabilities, improved the operational management system, consolidated its sales network, drove product quality and comprehensive market competitiveness growth, and fortified the resilience of lead-acid batteries in a complex market environment. Within the reporting period, the Group was able to effectively upgrade its manufacturing efficiency and supply-chain resilience through utilising intelligent manufacturing systems and equipment technology upgrades, while demonstrating effective results in cost management. Through the evolution of battery technologies and product upgrades, the Group constructed a differentiated product matrix targeting major fields of usage such as light electric vehicles, data centres, automobile start-stop batteries, and industrial power batteries,driving a service system upgrade with user value at its core, and organically merged the traditional sales network with an innovative digital ecosystem.Solidifying the Diversity of Technological Road-maps and Accelerating New Business Growth In the first half of 2025, the Group committed to the development of new-energy businesses, including Li-ion batteries, solid-state batteries, hydrogen fuel cells, and sodium-ion batteries, and systematically drove innovative breakthroughs, intelligent manufacturing upgrades, user-scenario extensions, and fostered new business growth. The Group’s Li-ion batteries business mainly targets power storage and low-speed power. Within the reporting period, the Group’s power storage and low-speed power business achieved major improvements both in terms of quality and quantity. Specific markets, such as industrial batteries and automobile A/C batteries, also saw improvements in market volume. Overall, the capacity utilisation of the Group’s new-energy business was significantly enhanced, with remarkable improvements in operational efficiency and revenue, RMB 0.501 billion, a 174.58% increase from the same period of 2024.The Group’s solid-state battery also achieved intermittent success within the three dimensions of high energy density, cycle longevity, and high-rate performance. The Group also formed strategic collaborations with industry leaders in the two-wheeled vehicle market and carried out solution testing with partners targeting the low-altitude flying vehicle market. The Group continued its investment in hydrogen fuel-cells with a full-chain R&D system and an expert team, with advanced products, began testing in user-scenarios such as two-wheeled vehicles, public transportation, heavy trucks, and special-purpose machinery, and collaborated with upstream and downstream partners in constructing an application ecosystem. The Group also spearheaded the development and application of sodium-ion battery technology, and conducted experiments for key metrics such as low-temperature and cycle longevity testing for scenarios such as power storage and automobile start-stop battery in a steady manner. Through the multi-roadmap approach, and the “technology breakthrough - user scenario verification - solution delivery” process, the Group’s new-energy business growth is gradually and steadily shifting from individual verification to chain-release, firmly supporting the business momentum.Strengthening the Recycling System and Fortifying Industrial CollaborationThe battery industry is at the core of the Group’s business, which systematically constructed a full-life industry chain of manufacturing, recycling, and reusing, forming a two-railed industry system of lead-acid battery and Li-ion battery, achieving efficient recycling. Within the reporting period, the recycling business of the Group achieved a revenue of RMB 1.8 billion, a 15.82% increase compared to the same period of 2024.As a leader in the recycling industry in China, the Group is continuously building an effective recycling network with front-end reach and back-end efficiency, promoting the efficiency of waste battery recycling empowered by the collaborative effort of businesses at scale, and achieving a top-of-industry recycling ratio of crucial materials. Within the reporting period, the Group continued to enhance the granularity and precision of the recycling process from recycling, processing, and reusing, improve the differentiating system for Li-ion battery recycling, and improve the resource synergies at core regions and user scenarios. Through uninterrupted exploration of technological potential and system performance optimisation, the Group was able to gradually achieve scale advantage and economic value of the recycling system, injecting continuous momentum for the industry.Looking forward, Tianneng will drive industrial upgrades through technological innovation, empower efficient operation through digitisation, rebuild the value-chain system through ecological collaboration, and seek growth through internationalisation. The Group will solidify its competencies in the lead-acid market, accelerate the research, application, and market expansion process of new energy batteries such as Li-ion battery and solid-state battery. The Group will strengthen its capabilities in battery recycling, enhance the collaborative efficiency of industry-chain integration while expediting its expansion into overseas markets and optimising localised operation, from product to service, and develop into a new-energy battery company that is competitive with a global vision. Finally, the Group will promote the convergence between its company values and social values with a growth mindset and build a new paradigm of sustainable and high-quality growth.About Tianneng Power International LimitedTianneng Power International Limited and its subsidiaries (collectively referred to as “Tianneng” or the “Company”), founded in 1986 and headquartered in China, has developed into a leading enterprise in the new energy battery and the light electric vehicle battery industry with a comprehensive manufacturing system and technological advantage. Tianneng was listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 00819. HK) in 2007. After nearly four decades of development, Tianneng has established lead-acid batteries as its core business, focusing on the market of motive batteries for light electric vehicles, while expanding its product in automotive start-stop systems, backup power for communication base stations and other diversified scenarios. The Company is also advancing the R&D, production and sales of lithium-ion batteries, hydrogen fuel cells, sodium-ion batteries and solid-state batteries, offering multi-technology battery solutions for special industrial vehicles, energy storage systems and other applications. Additionally, Tianneng strengthens its recycling economy initiatives around its core operations. Through a dual-track system for lead and lithium recycling, the Company achieves efficient resource regeneration and reuse, building a comprehensive ecosystem for the new energy industry. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"). The Group adopted “one horizontal, one vertical” as its core business strategy: horizontally, it extended a lean management system to advance multi-mode collaboration among medical institution alliances; vertically, it focused on specialty-specific innovation in medical diagnostics to fast-track the translation and implementation of new technologies and products. Meanwhile, the Group leveraged AI to enhance the comprehensive solutions for medical institution alliances, promoted the practical application of AI in healthcare scenarios, and continuously strengthened the value of empowering clinical practices, demonstrating strong operational resilience.In the first half of 2025, due to multiple factors, including the centralized drug-procurement program, cost controls of medical insurance, and fierce market competition, the Group’s short-term results did not meet expectations. However, the Group remained committed to product and business model innovation, and further refined the mechanisms and processes of its operational management. By adhering to lean operations, the overall performance has achieved significant improvements. During the Reporting Period, the Group’s gross profit margin reached approximately 34.0%, representing an improvement of approximately 4.4% over the overall gross profit margin for 2024. The net loss amounted to RMB55.4 million, a significant decrease of 56.1% compared to the same period last year. The joint construction business remained the Group’s largest business segment, which recorded the revenue of RMB180.3 million, accounting for 57.6% of the total revenue, increased by approximately 9.6% as compared with the same period last year, achieving significant outcomes in empowering medical alliance clients through in-depth services, paving the way for the Group’s long-term high-quality growth. During the Reporting Period, the Group’s diagnostic testing services recorded revenue of RMB313.2 millionSteadily implementing “one horizontal, one vertical” strategy, with notable achievements in hospital-enterprise partnerships“One horizontal” ——Extending lean management system to deepen diverse forms of collaboration within medical institution alliancesYunkang has been committed to developing an innovative service mode for the joint construction of medical institution alliances featuring “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. During the Reporting Period, the Group provided nearly 450 alliance clients with multi-scenario solutions tailored to different clinical needs, including AI+ digital intelligence solutions for medical institution alliances, comprehensive collaborations with medical laboratories, solutions for regional/pathology centers and precision medicine center, and specialty-based solutions for alliance development, among other multi-model collaboration services. By leveraging Yunkang’s strengths, the Group assisted healthcare institutions at all levels in enhancing service capabilities and expanding service coverage, established a hierarchical and coordinated healthcare service system, and promoted the development of regional hierarchical diagnosis and treatment services.During the Reporting Period, despite increasingly fierce market competition, the Group maintained solid growth in the joint construction business through continuous deep collaboration with leading hospitals and municipal and county-level hospitals, further consolidating its competitive advantage.“One vertical” ——Joint innovation platform for diagnostic testing serves as strong driver for R&DThe Group has always focused on “clinical needs”, continuously strengthening hospital-enterprise collaboration and pioneering the establishment of a joint innovation platform for diagnostic testing, driving business expansion and product competitiveness. During the Reporting Period, the Group forged joint diagnostic innovation partnerships with dozens of top-tier medical institutions nationwide, delivering a portfolio of testing products addressing multiple infectious syndromes, including respiratory tract infections, central nervous system infections, urinary tract infections, gynecological infections, and tuberculosis, as well as genetic testing products for personalized medication. Collectively, these innovative products have served nearly 300 clients across the country, and achieved sustained growth in testing revenue.During the Reporting Period, Yunkang and Guangdong Provincial People’s Hospital successively launched a series of new panel products covering respiratory tract infections, central nervous system infections, and invasive fungal infections, successfully creating a standardized incubation model for domestic hospital-enterprise research innovation and translation, as well as a “1+N” medical inspection collaboration network. Moreover, throughout the process of scientific and technological innovation, both parties have gained rich clinical experience. With the active involvement and sustained efforts of dozens of domestic diagnostic experts and scholars, they formulated the Expert Consensus on the Application of tNGS for Clinical Standardization, which was published during the Reporting Period in Chinese Journal of Laboratory Medicine, a leading journal in China’s diagnostic field. During the Reporting Period, Yunkang also maintained close collaboration with the First Affiliated Hospital of Guangzhou Medical University, one of China’s top-tier hospitals, and successfully developed a urinary tNGS product, advancing the clinical practice of precision diagnosis and treatment for urinary tract infections. Simultaneously, Yunkang partnered with the First Affiliated Hospital of Jinan University to establish a “university-hospital-enterprise joint innovation platform” and incubated and operated the “innovation project of psychiatric drug genetic testing”, which has successfully yielded genetic testing products for antidepressants, anti-anxiety drugs, and sedative-hypnotics.AI empowers multi-modal solutions for medical institution alliances, improving quality and efficiency to deepen client services  During the Reporting Period, Yunkang fully employed DeepSeek and achieved digital deployment across its platforms. Centered on the core concepts of “AI+” and “precision diagnostics”, Yunkang extensively applied artificial intelligence technology across the multi-technology platforms of its medical laboratories. Taking the in-depth integration of AI technology with Yunkang pathology diagnosis platform as an example, the per-slide efficiency of AI-empowered diagnostic was continuously optimized, achieving simultaneous improvements in intelligence, efficiency, and quality. Moreover, through the deployment of intelligent applications, Yunkang realized smart online customer services and the efficient review of results and reports, which fully streamlined diagnostic service processes and improved experience and satisfaction of its client services. In the process of jointly developing new technologies and products through hospital-enterprise R&D, Yunkang’s AI technology empowered product innovation and R&D across multiple aspects, including bioinformatics analysis, report interpretation, disease risk assessment, and development and translation of novel products, by leveraging the powerful data analysis, modeling, and predictive capabilities of large-scale AI models. This has accelerated the clinical implementation.Notably, Yunkang unveiled its medical AI model “ZhiYun” developed in collaboration with Runda Medical and Huawei, spanning the entire clinical workflow from pre-diagnosis to diagnosis and post-diagnosis. It will provide more efficient and convenient support and experience across all stages of clinical medical services. Meanwhile, Yunkang signed a strategic cooperation agreement with Runda Medical to strengthen in-depth collaboration across the industrial ecosystems in “AI + IVD + healthcare services”, jointly promoting the development and application of large-scale AI models in the medical field, and providing clients with digital-intelligence healthcare solutions. In the future, “ZhiYun”, the medical AI model, will be piloted in Yunkang’s healthcare partners and gradually rolled out nationwide, to improve quality and efficiency of medical institution alliance operations.Future prospects2025 marks the final lap for implementing the 14th Five-Year Plan. China has accelerated the capacity expansion of premium healthcare resources and their extension to lower-tier markets, resulting in a more balanced regional distribution. The country has also expedited the development of medical institution alliances and driven their upgrade from “framework building” to “high-quality operation”. Clinical treatment is also shifting from “broad-spectrum therapies” to “precision medicine”, with the growth potential of the industry continuing to be realized. At the same time, AI technology has continued to empower hierarchical diagnosis and treatment services, and the industry is embracing new growth opportunities.  Looking ahead, Yunkang will continue to keep pace with industry development trends and align with national policies, further strengthening the value of empowering clinical practices, and persistently exploring the “product innovation + business innovation” dual-pronged model to accelerate business development, deeply empower medical testing services, and benefit more residents.Yunkang Group Limited (Stock Code: 2325)Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to nearly 450 on-site diagnostic centers. As of June 30, 2025, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

Toronto, ON, August 28, 2025 - (ACN Newswire via SeaPRwire.com) - Digital Shovel, a leading innovator in crypto mining infrastructure solutions, is thrilled to announce the successful completion of its partnership with IREN (formerly Iris Energy Limited), marked by the delivery of the final batch totaling 493 MW of busway sets, including active units and spares. This milestone, achieved well ahead of schedule, underscores Digital Shovel’s commitment to excellence and reliability in supporting next-generation data center operations.The partnership, formalized in February 2024, saw Digital Shovel supply IREN with almost 500 MW of busways, critical to powering IREN’s expanding data centers, which are optimized for Bitcoin mining and AI cloud services using 100% renewable energy. The project was completed without delays, with deliveries consistently surpassing expectations, enabling IREN to advance its operational timeline.“We are incredibly proud of the seamless execution of this partnership with IREN,” said Scot Johnson, CEO of Digital Shovel. “Delivering all 493 MW of busway sets ahead of schedule is a testament to our team’s dedication and the strength of our innovative solutions. IREN’s vision for sustainable, high-performance data centers aligns perfectly with our mission, and we’re excited about the impact this project will have on their growth.”The early completion of this contract also positions both companies for future collaboration. “This project has been a fantastic opportunity to showcase what we can achieve together,” Johnson added. “We’re eager to explore new ventures with IREN as they continue to lead in renewable energy-powered data centers for Bitcoin mining and AI applications.”The success of this deployment lays the foundation for expanded collaboration as demand for infrastructure solutions continues to surge. With proven capacity to deliver at scale and speed, Digital Shovel is positioned to help power the next generation of energy-efficient data centers across North America.For more information about Digital Shovel and its solutions, please visit www.digitalshovel.com.About Digital ShovelDigital Shovel is a leading vertically integrated HPC, AI and Bitcoin Mining systems manufacturer, building critical elements for datacenter construction. This includes turnkey modular datacenters, as well as infrastructure including switchgear, Smart PDUs, busway systems and more. For more info, visit www.DigitalShovel.com About IRENIREN (NASDAQ: IREN), formerly Iris Energy Limited, is an Australia-based company operating next-generation data centers powered by 100% renewable energy. With facilities optimized for Bitcoin mining, AI cloud services, and other power-dense computing applications, IREN is a global leader in sustainable, high-performance data center solutions. For more information, visit www.iren.com.Media Contact:Press@DigitalShovel.comhttps://www.digitalshovel.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - On August 27, CALB Group Co., Ltd. ("CALB" or "the Company," stock code: 3931.HK) announced its unaudited condensed consolidated interim results for the six months ended 30 June 2025 (the "Reporting Period"). During the Reporting Period, the Company delivered outstanding operational performance with revenue of RMB16,418.88 million, representing an increase of 31.7% compared to the same period last year, and realized a profit of RMB752.99 million, representing a year-on-year increase of 80.4%. In the first half of 2025, the Company showed strong profitability and resilience during the accelerated trend of transformation of global renewable energy development.According to SNE Research, the Company’s installed capacity of globally EV batteries in the first half of 2025 increased 22.7%, ranking third domestically and fourth globally, with the monthly installed capacity reaching 4.7GWh. The Company was particularly outstanding in the domestic passenger vehicle market with the market share hitting new highs in June and July, reaching 7.4% and 8.25%, respectively. In the energy storage sector, the Company's growth was even more rapid. According to InfoLink, the Company’s shipment in the first half of the year ranked fourth globally, achieving milestone development in the energy storage sector.Centered on continuous technological breakthroughs and with the launch of multiple major products, in the first half of 2025, the Company maintained its leadership in cutting-edge battery technology with the “UP” battery. At the same time, the Company’s 400Wh/kg solid-liquid hybrid battery is poised for mass production and commercial deployment, while significant progress has been made in the all-solid-state battery—including breakthroughs in R&D and the commissioning of a dedicated production line. CALB’s high-power lithium iron phosphate R46 large cylindrical battery is the first in the industry to achieve mass production and has successfully achieved mass production for the latest PHEV models from Geely and Dongfeng. At the same time, the Company’s next-generation lithium manganese LFP battery product achieves an energy density exceeding 210Wh/kg and will also go into mass production. With improved performance, the product can attain 10%- 80% charging within 15 minutes.In the passenger vehicle market, leveraging exceptional product capabilities, the Company achieved full entry into the world’s top three automakers, namely Volkswagen, Hyundai and Toyota. In the first half of 2025, its 800V 5C batteries achieved a monthly sales volume of over 20,000 packs, which will support models for XPeng, Ledao, Leapmotor, Audi, BAIC, and others, and the 800V 5C high-voltage NCM battery exclusively supports popular models such as XPeng’s new P7 with ultra-long range, helping XPeng’s new P7 create a new world record of driving 3,971km in 24 hours.In the commercial vehicle market, CALB has established a comprehensive product matrix architecture for “ZHIYUAN” batteries, covering all scenarios, all applications, and all capabilities. In the first half of year, the Company’s domestic commercial vehicle installed capacity has increased by 310% year-on-year. CALB is the first in the industry to launch a million-kilometer customized products for light trucks, significantly improving the quality assurance of battery systems and effectively enhancing product competitiveness in the market. Leveraging the outstanding recognition from the light truck field, the Company has established in-depth collaborations with customers such as Chery, Geely, Ruichi, Foton, Dongfeng, Changan, and King Long. In the heavy truck field, the Company has deeply cultivated the market through the scenario-based power consumption design and has achieved full-spectrum collaboration by partnering with customers such as Sinotruk, XCMG, SANY, Shaanxi Automobile, Jiefang, Dongfeng, Lingong, and Liugong.The Company has made significant breakthroughs in the international market, and its energy storage business achieved rapid growth in the first half of year. The 314Ah second-generation long-cycle energy storage cell can achieve an ultra-long service life of 15,000 cycles and high energy efficiency of over 96%, while achieving zero degradation in the first 1,000 cycles, earning high recognition from customers for both the product and delivery capabilities. In terms of the overseas market, the Company has successfully partnered with the largest power plant projects in Latin America and South Africa, entering the supplier lists of several leading developers and power grid companies. Meanwhile, the Company’s next-generation “ZHIJIU” of 588Ah and 600Ah+ large energy storage cells will scheduled for mass production within the year.In addition, the Company is the first in the industry to pass the eVTOL power battery manufacturing compliance review and supports the development of China’s low-altitude economy market by actively exploring emerging markets. At present, the R46 cylindrical battery cell with an energy density of 310Wh/kg is now in mass production for leading eVTOL customers in the industry. At the same time, CALB signed a deepened strategic cooperation agreement with GOVY, under which the two parties will carry out in-depth collaboration in the eVTOL sector and jointly promote the development of standardized eVTOL energy products.Overall, in the first half of the year, CALB focused on the strategy of consolidating its leadership in products and technologies, while accelerating the globalization of its production capacity layout. At present, its battery Pack plant in Thailand has been put into operation, while construction of the Portugal base officially commenced in the first quarter of 2025. Looking ahead, with the further improvement of industrial chain system, the Company is expected to leverage its cross-domain, cross-scenario dynamic storage product matrix to achieve deep synergy in its dynamic storage business, creating cutting-edge product capabilities across all scenarios. At the same time, the Company will continuously explore emerging markets such as rail transit, mining, low-altitude flight, and humanoid robots by offering high-safety, high-reliability, and high-performance product solutions. Furthermore, CALB will continue to advance the implementation of its “energy+” strategy, further consolidating its leading position in the global new energy industry.About CALBCALB is a new energy enterprise specializing in the research, production, sales, and market application development of lithium batteries, battery management systems, and related integrated products and lithium battery materials. As Battery Expert, we aim to build a comprehensive energy operation system, to provide complete product solutions and full life-cycle management for the new energy application market, represented by power and energy storage.Currently, CALB has completed an all-round layout in domestic by setting up industrial bases in Changzhou, Xiamen, Wuhan, Chengdu, Hefei, Jiangmen and Meishan. Meanwhile, CALB has set up bases in Europe and ASEAN, vigorously expanding the layout all over the world to become a global leading enterprise with large-scale intelligent manufacturing capabilities. Copyright 2025 ACN Newswire via SeaPRwire.com.